サンプル依頼リスト カート
  • English
  • Korean
表紙：通年性アレルギー性鼻炎の世界市場：2023年～2030年
市場調査レポート
商品コード
1382550

通年性アレルギー性鼻炎の世界市場：2023年～2030年

Global Perennial Allergic Rhinitis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
通年性アレルギー性鼻炎の世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

通年性鼻炎は臨床的には、鼻閉、くしゃみ、かゆみ、鼻出血を特徴とする鼻の炎症性疾患で、1年を通してほとんどの日に1時間以上起こるものと定義されます。鼻炎は、一次医療と二次医療の両方の医師によって一般的に管理されています。ほとんどの症例は一次医療で診断・治療できますが、患者が治療に反応しない場合や他の診断が疑われる場合には、二次医療への紹介が必要となることが多いです。

市場力学：促進要因と阻害要因

アレルギー性鼻炎有病率の上昇

世界の疾患であるアレルギー性鼻炎（AR）は、世界中の膨大な数の人々が罹患しています。アレルギー性鼻炎は、鼻に影響を及ぼす一連の症状で診断されます。これらの症状は、ホコリや動物のフケ、花粉など、アレルギーの原因となるものを吸い込んだときに起こります。

アレルギー性鼻炎と喘息の増加は比較的急速に起こったため、遺伝的要因の変化がアレルギー性疾患の増加の根本的原因であるとは考えにくいです。その代わりに、複数の環境要因が関与している可能性があります。衛生状態の改善、寄生虫感染の根絶、家庭の暖房や換気の変化、ライフスタイルの変化による身体活動の低下や食生活の変化などです。

アレルギー性鼻炎の有病率の上昇は、予測期間中に生理食塩水スプレー市場を牽引する重要な主要要因の一つです。例えば、National Library of Medicine 2023に掲載された論文によると、AR症例の有病率は2017年から2022年の間に1.83%から9.23%に及びました。COVID-19パンデミックの前後では、21.38～70.22％と大幅な減少がみられました。6歳から18歳では、女性よりも男性の方が流行率が高い傾向にあります。このように、上記の要因が予測期間中の市場成長を後押ししています。

さらに、より効果的な製品や製剤の開拓のための継続的な広範な研究開発活動、環境条件の変化、新興国市場の汚染、患者数の増加、ライフスタイルの変化が、通年性アレルギー性鼻炎市場の主要な促進要因であることを証明しています。

市場力学：阻害要因

アレルギー性鼻炎は、睡眠障害、疲労、過敏性、抑うつ、注意困難などを引き起こす深刻な健康状態です。治療せずに放置すると慢性化し、鼻炎、副鼻腔炎、中耳炎、睡眠時無呼吸、上気道感染、歯の問題、耳管機能不全などの合併症を引き起こす可能性があります。また、喘息を発症する可能性の増加、喘息の再燃、症状の悪化、すでに喘息を持っている人のコントロール困難な喘息とも関連しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • アレルギー性鼻炎の有病率の上昇
      • より効果的な製品・製剤開発のための継続的な大規模研究開発活動
    • 抑制要因
      • 通年性アレルギー性鼻炎治療薬に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 薬剤クラス別

  • 抗ヒスタミン薬
  • ステロイド
  • 鬱血除去剤
  • アレルゲン免疫療法製剤
  • その他

第8章 投与経路別

  • 経口
  • 経鼻
  • 筋肉内

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • AdenHealthcare
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Niprojmipharma
  • Krosyl Pharma
  • Sanis Health Inc
  • Hanmi Pharma
  • Johnson & Johnson Consumer Inc.
  • Bristol Laboratories Ltd
  • GSK
  • Nutra Respiro
  • Bayer Canada

第13章 付録

目次
Product Code: PH7474

Overview

Perennial rhinitis can be defined clinically as an inflammatory condition of the nose characterised by nasal obstruction, sneezing, itching, or rhinorrhoea, occurring for an hour or more on most days throughout the year. Rhinitis is commonly managed by both primary and secondary care physicians. Although most cases can be diagnosed and treated in primary care, referral to secondary care is often necessary when patients do not respond to treatment or other diagnoses are suspected.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of allergic rhinitis

A global disease allergic rhinitis (AR) affects a huge proportion of people around the world. Allergic rhinitis is diagnosed with a group of symptoms affecting the nose. These symptoms occur when people breathe in something they are allergic to, such as dust, animal dander or pollen.

Changes in genetic factors are unlikely to be the underlying cause of the rise in allergic diseases since the increases in allergic rhinitis and asthma occurred relatively rapidly. Instead, multiple environmental factors may have played a role. These include improvements in hygiene, eradication of most parasitic worm infections, changes in home heating and ventilation, and a decline in physical activity and alterations in diet due to lifestyle changes.

The rise in the prevalence of allergic rhinitis is one of the significant key factors that drive the saline spray market during the forecast period. For instance, according to the article published in the National Library of Medicine 2023, the prevalence of AR cases ranged from 1.83 to 9.23% between 2017 and 2022. There was a significant drop of 21.38 to 70.22% between the pre- and post-COVID-19 pandemic. Males were more prevalent in the 6 to 18-year-olds than females. Thus, the above factors help to drive market growth during the forecast period.

Furthermore, ongoing extensive R&D activities for the development of more effective products and formulations, changes in environmental conditions, increasing pollution, rising number of patients, and changes in lifestyle are proving the major driving factors for the perennial allergic rhinitis market.

Market Dynamics: Restraint

Allergic rhinitis is a serious health condition that can lead to sleep disturbances, fatigue, irritability, depression, and difficulty paying attention. If left untreated, it can become chronic and lead to complications such as nasal inflammation, sinusitis, otitis media, sleep apnea, upper respiratory tract infection, dental problems, and eustachian tube dysfunction. It is also linked to increased chances of developing asthma, flares, worsening symptoms, and difficult-to-control asthma in those with existing asthma.

Segment Analysis

The global perennial allergic rhinitis drugs market is segmented based on drug class, route of administration, distribution channel and region.

The anti-histamines segment from the drug class segment accounted for approximately 41.7% of the perennial allergic rhinitis drugs market share

The anti-histamines segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Antihistamines are a pharmaceutical class of drugs that act to treat histamine-mediated conditions. There are two main classes of histamine receptors: H-1 receptors and H-2 receptors. Antihistamine drugs that bind to H-1 receptors are generally used to treat allergies and allergic rhinitis.

For instance, in June 2021, the U.S. Food and Drug Administration approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis-commonly known as allergies-for adults and children six years of age and older.

Geographical Analysis

Europe accounted for approximately 31.4% of the market share in 2022

Europe is estimated to hold about 31.4% of the total market share throughout the forecast period, owing to the rise in the prevalence of perennial allergic rhinitis, novel drug launches, rise in research and development, well-established market players, collaborations and acquisition with key players and others help this region to be having highest market share during the forecast period.

For instance, in April 2021, Glenmark Pharma stated that it is concluding the final, national phase of its marketing approval application process to launch its nasal spray Ryaltris in 17 countries in the European Union (EU). Glenmark said Ryaltris is now approved in Europe for the first-line treatment of allergic rhinitis in patients over 12 years of age. Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

COVID-19 Impact Analysis

A study conducted by an investigative otolaryngology group they found that many patients with allergic rhinitis symptoms worsened due to increased exposure to indoor allergens and discontinuation of immunotherapy during COVID-19 lockdowns. The study emphasizes the importance of long-term management, primary prevention, and control through allergen avoidance measures, pharmacotherapy, and allergen-SIT. Environmental factors are critical in AR pathogenesis, and immunotherapy remains the only treatment that alters the disease's natural history.

Market Segmentation

By Drug Class

  • Anti Histamines
  • Steroids
  • Decongestants
  • Allergen Immunotherapy formulations
  • Others

By Route of Administration

  • Oral
  • Nasal
  • Intramuscular

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

major global players in the market include: AdenHealthcare, Niprojmipharma, Krosyl Pharma, Sanis Health Inc, Hanmi Pharma, Johnson & Johnson Consumer Inc, Bristol Laboratories Ltd, GSK, Nutra Respiro, Bayer Canada and among others.

Key Developments

  • In July 2023, Altamira Therapeutics Ltd, a company dedicated to developing therapeutics that address important unmet medical needs, stated that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.

Why Purchase the Report?

  • To visualize the global perennial allergic rhinitis drugs market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analysing trends and co-development.
  • Excel data sheet with numerous data points of perennial allergic rhinitis drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global perennial allergic rhinitis drugs market report would provide approximately 61 tables, 58 figures and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of allergic rhinitis
      • 4.1.1.2. Ongoing extensive R&D activities for the development of more effective products and formulations
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the perennial allergic rhinitis drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Anti Histamines *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Steroids
  • 7.4. Decongestants
  • 7.5. Allergen Immunotherapy formulations
  • 7.6. Others

8. By Route of administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Nasal
  • 8.4. Intramuscular

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. Australia
      • 10.5.5.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. AdenHealthcare*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Niprojmipharma
  • 12.3. Krosyl Pharma
  • 12.4. Sanis Health Inc
  • 12.5. Hanmi Pharma
  • 12.6. Johnson & Johnson Consumer Inc.
  • 12.7. Bristol Laboratories Ltd
  • 12.8. GSK
  • 12.9. Nutra Respiro
  • 12.10. Bayer Canada

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us